Associated Papers
Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: A case study and implications for precision oncology.
Nishiyama A et al.
Cancer Science, 2025
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_3.xlsx › EGFR_mutations
Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Cocco E et al.
Nature Medicine, 2019
31406350 (PubMed )
Supplement: NIHMS1533563-supplement-1.xlsx › Patient_8
Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients.
Deng Q et al.
Heliyon, 2018
30603682 (PubMed )
Supplement: mmc2.xlsx › Raw_reads_info
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.
Unni AM et al.
Elife, 2015
26047463 (PubMed )
Supplement: elife06907s001.xlsx › Sheet1
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
A growing family: adding mutated Erbb4 as a novel cancer target.
Rudloff U et al.
Cell Cycle (georgetown, Tex.), 2010
Select a paper to view details